NCT05751434 A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
| NCT ID | NCT05751434 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | City of Hope Medical Center |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2026-07-13 |
| Primary Completion | 2028-08-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 102 participants in total. It began in 2026-07-13 with a primary completion date of 2028-08-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Men with histologically confirmed localized prostate cancer undergoing active surveillance. * Inactive, defined as not meeting the national exercise guidelines for cancer patients (\<150 minutes/week of moderate or vigorous exercise)43 as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry (general physical activity screening assessment via smart watch). * Screening clearance by an MSK Exercise Physiologist (i.e., review of ECG) * BMI \<40 kg/m\^2 * Cleared for exercise participation as per pre-screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) (Appendix B) Exclusion Criteria: * Enrollment in any other program that may alter the impact of exercise on tumor outcomes (e.g., weight loss program) * Any neoadjuvant anticancer treatment of any kind for prostate cancer in the last 5 years * Any history of systemic anticancer therapy in the last 15 years * Distant metastatic malignancy of any kind * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
Contact & Investigator
Lee Jones
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT05751434 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05751434 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05751434 currently recruiting?
Yes, NCT05751434 is actively recruiting participants. Contact the research team at leejones@coh.org for enrollment information.
Where is the NCT05751434 trial being conducted?
This trial is being conducted at Duarte, United States, Los Angeles, United States, Hartford, United States, Basking Ridge, United States and 6 additional locations.
Who is sponsoring the NCT05751434 clinical trial?
NCT05751434 is sponsored by City of Hope Medical Center. The principal investigator is Lee Jones at City of Hope Medical Center. The trial plans to enroll 102 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.